Abstract
Previous studies have suggested that interleukin-10 (IL-10) polymorphisms may be associated with an increased risk of developing cervical cancer. However, the published results on this subject matter are controversial. The aim of this study was to conduct a meta-analysis of published reports to more precisely investigate the relationship between IL-10 polymorphisms and cervical cancer risk. Five online databases (PubMed, Embase, Web of SCI, CNKI and Wanfang) were searched, and seventeen articles with sufficient quantitative information were included in our meta-analysis. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the association between IL-10 polymorphisms and cervical cancer risk. Publication bias, sensitivity and cumulative analyses were also performed to support our findings. Overall, there was a significant association between the IL-10 -1082A > G polymorphism and cervical cancer risk observed in the total population (G vs. A: OR = 1.60, 95% CI = 1.12–2.29, P = 0.01, I2 = 92.3%; AG vs. AA: OR = 1.34, 95% CI = 1.04-1.74, P = 0.03, I2 = 65.9%; AG + GG vs. AA: OR = 1.58, 95% CI = 1.11–2.25, P = 0.01, I2 = 84.4%), and the same results were obtained in the subgroup analysis. Moreover, the IL-10 -819 T > C polymorphism exhibited a significant, protective effect against cervical cancer. In summary, our meta-analysis suggests that IL-10 polymorphisms may play a variety of roles in regard to cervical cancer risk, especially in Asians.
Highlights
In 2012, there were an estimated 527,600 new cervical cancer cases and 265,700 deaths from cervical cancer worldwide, mostly affecting developing countries [1].Cervical cancer affects the cervix and encompasses squamous cell carcinomas (90%), adenocarcinoma (10%), and other subtypes [2, 3]
Previous studies have suggested that interleukin-10 (IL-10) polymorphisms may be associated with an increased risk of developing cervical cancer
For the IL-10 -592C > A polymorphism, ten studies consisting of 3,149 cases and 2,237 controls were pooled in the meta-analysis to assess whether this IL-10 -592C
Summary
In 2012, there were an estimated 527,600 new cervical cancer cases and 265,700 deaths from cervical cancer worldwide, mostly affecting developing countries [1]. Cervical cancer affects the cervix and encompasses squamous cell carcinomas (90%), adenocarcinoma (10%), and other subtypes [2, 3]. A combination of Cervical cancer is the second most common form of cancer diagnosed in women and the third leading cause of death from cancer. Www.impactjournals.com/oncotarget surgery, radiotherapy and chemotherapy is still the most effective form of treatment for cervical cancer [4,5,6]. A variety of risk factors, such as chronic inflammation, unhealthy living conditions, and human papillomavirus (HPV) infections have been proven to increase the risk of cervical tumorigenesis [10–
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
